FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890961795> ?p ?o ?g. }

• W2890961795 abstract "Introduction Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated for ulcerative colitis (UC). The efficacy and safety of tofacitinib was demonstrated as induction and maintenance therapy in 3 Phase 3, randomised, placebo-controlled studies (OCTAVE Induction 1, NCT01465763; OCTAVE Induction 2, NCT01458951; OCTAVE Sustain, NCT01458574) in patients (pts) with moderate to severe UC.1 Methods We present interim safety and efficacy data up to 3 years of treatment (as of 8 July 2016) from an ongoing Phase 3, multicentre, open-label, long-term extension study (OLE; NCT01470612) in pts who had completed or demonstrated treatment failure in OCTAVE Sustain, or who were non-responders after completing OCTAVE Induction 1 or 2. Pts in remission at Week 52 of OCTAVE Sustain received tofacitinib 5 mg twice daily (BID); all others received 10 mg BID. At Month 2, all pts underwent endoscopy, and non-responders from Induction were mandated to withdraw if no evidence of clinical response was shown. Remission was defined by a Mayo score ≤2 with no individual subscore >1, and rectal bleeding subscore of 0. Binary efficacy endpoints were derived from Mayo score, based on local-read endoscopic subscore. Results 914 pts (5 mg BID, n=156 [17.1%]; 10 mg BID, n=758 [82.9%]) received ≥1 dose of study drug; 381 pts (41.7%) discontinued. The most frequent AE leading to discontinuation was worsening of UC. The most frequent treatment-emergent AEs by system organ class (both doses) were ‘infections/infestations’ and ‘gastrointestinal disorders’, and by preferred term were ‘nasopharyngitis’ and ‘worsening of UC’. Serious infections AEs were reported in 4 (2.6%) and 14 (1.8%) pts with 5 and 10 mg BID, respectively. Malignancies excl. NMSC were reported in 9 (1.2%) pts in the 10 mg BID group (no clustering of malignancy type); none were reported in the 5 mg BID group. No new safety risks were identified. Data ‘as observed’ for remission and mucosal healing at Months 2, 12 and 24 are shown. Conclusions In pts with moderate to severe UC who remained in the OLE study, no new safety concerns emerged compared with those observed with tofacitinib in rheumatoid arthritis. Efficacy results from this OLE study support sustained efficacy with tofacitinib 5 and 10 mg BID. Funded by Pfizer Inc. Reference 1. Sandborn WJ, et al. N Engl J Med 2017;376:1723–36." @default.
• W2890961795 created "2018-09-27" @default.
• W2890961795 creator A5018393711 @default.
• W2890961795 creator A5020827915 @default.
• W2890961795 creator A5024936486 @default.
• W2890961795 creator A5031236528 @default.
• W2890961795 creator A5035586844 @default.
• W2890961795 creator A5044524314 @default.
• W2890961795 creator A5051873692 @default.
• W2890961795 creator A5056735741 @default.
• W2890961795 creator A5080753060 @default.
• W2890961795 creator A5089342651 @default.
• W2890961795 date "2018-06-01" @default.
• W2890961795 modified "2023-09-28" @default.
• W2890961795 title "PTU-001 Tofacitinib, an oral jak inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study" @default.
• W2890961795 doi "https://doi.org/10.1136/gutjnl-2018-bsgabstracts.123" @default.
• W2890961795 hasPublicationYear "2018" @default.
• W2890961795 type Work @default.
• W2890961795 sameAs 2890961795 @default.
• W2890961795 citedByCount "0" @default.
• W2890961795 crossrefType "proceedings-article" @default.
• W2890961795 hasAuthorship W2890961795A5018393711 @default.
• W2890961795 hasAuthorship W2890961795A5020827915 @default.
• W2890961795 hasAuthorship W2890961795A5024936486 @default.
• W2890961795 hasAuthorship W2890961795A5031236528 @default.
• W2890961795 hasAuthorship W2890961795A5035586844 @default.
• W2890961795 hasAuthorship W2890961795A5044524314 @default.
• W2890961795 hasAuthorship W2890961795A5051873692 @default.
• W2890961795 hasAuthorship W2890961795A5056735741 @default.
• W2890961795 hasAuthorship W2890961795A5080753060 @default.
• W2890961795 hasAuthorship W2890961795A5089342651 @default.
• W2890961795 hasConcept C126322002 @default.
• W2890961795 hasConcept C141071460 @default.
• W2890961795 hasConcept C142724271 @default.
• W2890961795 hasConcept C204787440 @default.
• W2890961795 hasConcept C27081682 @default.
• W2890961795 hasConcept C2776233030 @default.
• W2890961795 hasConcept C2776694085 @default.
• W2890961795 hasConcept C2777575956 @default.
• W2890961795 hasConcept C2778283404 @default.
• W2890961795 hasConcept C2778715236 @default.
• W2890961795 hasConcept C2778886723 @default.
• W2890961795 hasConcept C2779134260 @default.
• W2890961795 hasConcept C2780479503 @default.
• W2890961795 hasConcept C535046627 @default.
• W2890961795 hasConcept C61943457 @default.
• W2890961795 hasConcept C71924100 @default.
• W2890961795 hasConcept C90924648 @default.
• W2890961795 hasConceptScore W2890961795C126322002 @default.
• W2890961795 hasConceptScore W2890961795C141071460 @default.
• W2890961795 hasConceptScore W2890961795C142724271 @default.
• W2890961795 hasConceptScore W2890961795C204787440 @default.
• W2890961795 hasConceptScore W2890961795C27081682 @default.
• W2890961795 hasConceptScore W2890961795C2776233030 @default.
• W2890961795 hasConceptScore W2890961795C2776694085 @default.
• W2890961795 hasConceptScore W2890961795C2777575956 @default.
• W2890961795 hasConceptScore W2890961795C2778283404 @default.
• W2890961795 hasConceptScore W2890961795C2778715236 @default.
• W2890961795 hasConceptScore W2890961795C2778886723 @default.
• W2890961795 hasConceptScore W2890961795C2779134260 @default.
• W2890961795 hasConceptScore W2890961795C2780479503 @default.
• W2890961795 hasConceptScore W2890961795C535046627 @default.
• W2890961795 hasConceptScore W2890961795C61943457 @default.
• W2890961795 hasConceptScore W2890961795C71924100 @default.
• W2890961795 hasConceptScore W2890961795C90924648 @default.
• W2890961795 hasLocation W28909617951 @default.
• W2890961795 hasOpenAccess W2890961795 @default.
• W2890961795 hasPrimaryLocation W28909617951 @default.
• W2890961795 isParatext "false" @default.
• W2890961795 isRetracted "false" @default.
• W2890961795 magId "2890961795" @default.
• W2890961795 workType "article" @default.